Infections with H. pylori affect over 43 percent of the world’s population with a wide range of gastrointestinal disorders
Mankind Pharma will have exclusive rights to register, import, market, sell and distribute sintilimab in India
Enhertu demonstrated clinically meaningful efficacy in previously treated patients
The drug will be marketed in different strengths of 150 mg and 440 mg and used in the treatment of patients with HER2
If approved, the Opdivo-based regimen would be the first immunotherapy-chemotherapy combination approved for this patient population in the EU
Submission to be reviewed under FDA real-time oncology review and Project Orbis
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
KEYTRUDA is the first immunotherapy approved in the EU for the first-line treatment of this patient population
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Subscribe To Our Newsletter & Stay Updated
